SCHEMBL7989066

SCHEMBL7989066

O=[C]OCOC(=O)c1ccncc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.50
KDM4E B2RXH2 6/20 0.49
TSHR P16473 3/20 0.49
KMT2A Q03164 3/20 0.49
GLA P06280 1/20 0.49
RAB9A P51151 1/20 0.49
LMNA P02545 2/20 0.47
HSD17B10 Q99714 1/20 0.47
ALDH1A1 P00352 4/20 0.44
AGTR1 P30556 1/20 0.44
MEN1 O00255 2/20 0.43
MAPT P10636 1/20 0.43
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
ADRB3 P13945 1/20 0.43
POLB P06746 2/20 0.42
MAPK1 P28482 1/20 0.42
SNCA P37840 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11125513 0.84 L3MBTL1 (0.49) L3MBTL1KDM4ETSHRKMT2AGLA
SCHEMBL844800 0.81 TDP1 (0.55) L3MBTL1KDM4ETSHRKMT2ARAB9A
SCHEMBL1813902 0.80 KMT2A (0.57) L3MBTL1KDM4EKMT2ALMNAALDH1A1
SCHEMBL15953935 0.77 L3MBTL1 (0.59) L3MBTL1KDM4ETSHRKMT2AGLA
SCHEMBL7989068 0.75 L3MBTL1 (0.50) L3MBTL1KDM4ETSHRKMT2AGLA
SCHEMBL21219622 0.75 KDM4E (0.61) L3MBTL1KDM4ETSHRKMT2AGLA
SCHEMBL21219627 0.75 KDM4E (0.61) L3MBTL1KDM4ETSHRKMT2AGLA
SCHEMBL3961850 0.75 HSD17B10 (0.55) L3MBTL1KDM4ETSHRKMT2AGLA
SCHEMBL18312846 0.74 L3MBTL1 (0.53) L3MBTL1KDM4ETSHRKMT2AGLA
SCHEMBL19688301 0.73 TDP1 (0.59) L3MBTL1KDM4ETSHRKMT2AGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130005730-A1 NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS MEDIVIR AB (SE) 2013-01-03 US disclosed
EP-2499120-A1 NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS Novadex Pharmaceuticals AB (SE) 2012-09-19 EP disclosed
US-6265418-B1 ANTICOAGULANTS UBE INDUSTRIES, LTD. (JP) 2001-07-24 US disclosed
EP-1020467-A1 N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF UBE INDUSTRIES LIMITED (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005730-A1 NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS REN, AGTR1, ACE L3MBTL1 4710/4885KDM4E 3318/4885TSHR 3403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.